The average price of 67 new drugs added by the National Medical Insurance Drugs has been reduced by 61.71%!

On December 3, the National Medical Security Administration held a press conference to announce the results of the 2021 National Medical Insurance Drug List
.
After review, 7 kinds of non-exclusive drugs outside the catalog were directly transferred, 11 kinds of drugs with low clinical value, strong substitutability, and small purchases on the national recruitment platform in recent years were transferred from the original catalog, and 117 drugs Be included in the scope of negotiations
.
From the results of the negotiation, 94 drugs (67 out of the list and 27 in the list) were negotiated successfully, with an overall success rate of 80.
34%
.
The average price of 67 drugs outside the catalogue was reduced by 61.
71%
.
Huang Huabo, director of the Fund Supervision Department of the National Medical Security Administration, said that the scope of the 2021 National Medical Insurance Drug List adjustment includes drugs newly marketed or modified in the label in the past five years, national essential drugs, and drugs used for the treatment of new coronary pneumonia
.
The newly-incorporated drugs accurately complement the medication needs of tumors, chronic diseases, anti-infections, rare diseases, women and children, and involve a total of 21 clinical groups.
Patients benefit from a wide range of drugs, and the availability and fairness of medications for the masses has been further improved
.
After adjustment, the total number of drugs in the National Medical Insurance Drug List in 2021 will be 2,860, of which 1,486 are Western medicines and 1,374 are Chinese patent medicines
.
There are still 892 kinds of Chinese herbal medicines in the catalog without adjustment
.
The new medical insurance catalogue will be implemented on January 1, 2022
.
"In the process of adjustment, the National Medical Security Administration has always adhered to the functional positioning of'guaranteeing basic', taking the affordability of funds as the'bottom line' that must be adhered to, and striving to meet the basic drug needs of the majority of insured persons
.
" Huang Huabo said
.
The new drugs added by the National Talks are basically on the market within 5 years.
The 7 non-exclusive drugs directly transferred into the catalog are all injections, covering tumor, nerve, cardiovascular, analgesic and other fields
.
They are: glycopyrrolate injection, ibuprofen injection, bendamustine hydrochloride for injection, citicoline sodium and sodium chloride injection, citicoline sodium and glucose injection, isosorbide chloride nitrate Sodium Injection, Isosorbide Nitrate and Glucose Injection
.
Glycopyrronium Bromide Injection is Hengrui Medicine's first imitation product and was approved for marketing in October 2020
.
Glycopyrrolate is an anticholinergic drug
.
Compared with atropine, glycopyrrolate has a smaller effect on the heart and a lower incidence of tachyarrhythmias
.
The "Expert Consensus on the Rational Use of Muscle Relaxants" issued by the Chinese Medical Association Anesthesiology Branch in 2017 clearly stated: "Glycopyrrolate is the first choice for Neostigmine
.
" At present, glycopyrrolate tablets and glycopyrrolate are available in China.
Ammonium bromide inhalation powder and aerosol capsules were approved for marketing
.
In the field of injections, in addition to Hengrui, Jiangsu Coast, Chengdu Yuandong, and Guangdong Jiabo have submitted ANDA applications.
No approval information is currently available
.
The reporter learned that the R&D layout of ibuprofen injection is very hot.
Since 2010, some enterprises have applied for clinical application, and 73 companies have had application records
.
At present, there are 4 companies whose generic drugs have been approved for listing, namely Chengdu Yuandong, Jilin Sihuan, Hangzhou Minsheng, and Chengdu Beite
.
Bendamustine hydrochloride for injection is a blockbuster product in the field of anti-tumor
.
At present, the companies that have been approved for generic drugs are CP Tianqing and Simcere TECO
.
The Insight database of Dingxiangyuan shows that there are still 14 domestic companies developing bendamustine hydrochloride for injection
.
According to data given by Liu Guoen, director of Peking University's China Health Economic Research Center and professor of Peking University's National Development Research Institute, 66 of the 67 new medical insurance products negotiated are products that will be listed within 5 years, and only 1 is not a product that will be listed within 5 years.

.
Many of them were insured the year they went public
.
Shi Yuankai, vice president of the Cancer Hospital of the Chinese Academy of Medical Sciences, pointed out that among the newly added drugs in the medical insurance catalogue in 2021, there are 18 types of oncology drugs, covering lung cancer, lymphoma, breast cancer, liver cancer, gastric cancer, myeloma, prostate cancer and neuroendocrine tumors.
And other fields
.
Take vometinib, a new domestic drug, for example, which was approved for marketing by the National Food and Drug Administration in March 2021 and belongs to the third-generation EGFR TKI
.
Among Chinese lung adenocarcinoma patients, about 50% have sensitive mutations in the EGFR gene, and about 50%-60% of patients will develop EGFR T790M mutations after receiving first-generation EGFR TKI treatment.
For patients with EGFR T790M mutations, third-generation EGFR TKI is the treatment.
Preferred
.
The three generations of EGFR TKIs currently on the market in China include osimertinib, ametinib, and vometinib.
Both osimertinib and ametinib have entered the medical insurance catalog.
The entry of vomitinib into the medical insurance catalog allows lung cancer patients to have With more treatment options, it is of great help to reduce the burden of treatment costs for patients
.
In addition, this adjustment also included some new targeted drugs, such as vedicitumumab
.
Vidicuzumab is China's first original HER2 antibody conjugate drug, and it has achieved good results in gastric cancer, breast cancer and other tumors
.
Although the drug has a definite effect, its high price leaves many patients beyond the reach
.
This time, the price of vedicitumumab was successfully reduced and entered the medical insurance, which benefited more cancer patients
.
After the entry of abecili, daratumomab, and vedicitumumab into the medical insurance list, they have filled the guarantee gap.
While raising the drug guarantee for breast cancer, gastric cancer, and myeloma to the international mainstream drug level, it has greatly increased Reduce the burden on patients
.
Part of the indications included in the medical insurance reimbursement catalog has also attracted much attention
.
Taking PARP inhibitors as an example, four PARP inhibitors participated in medical insurance negotiations this year.
Among them, the domestically-made innovative PARP inhibitor niraparib was successfully negotiated during the agreement period
.
A total of 507 new drugs have been added in 4 years.
According to Long Xuewen, deputy director of the Medical Security Management Center of the National Medical Security Administration, this adjustment of the medical insurance catalog is divided into 5 stages: preparation stage, application stage, expert review stage, negotiation stage, Announce the results
.
At the application stage, a total of 501 pieces of enterprise application information were received, involving 474 drugs
.
After review, publicity, and review, 273 drugs finally passed the formal review, of which 174 were not listed.

.
Since the establishment of the National Medical Insurance Bureau, the National Medical Insurance Drug List has been adjusted for 4 consecutive years.
A total of 507 drugs have been added to the scope of national medical insurance payment.
At the same time, a batch of "magic drugs" and "zombie drugs" have been removed from the list, leading the way in drugs.
The user end has undergone profound changes
.
In addition, six batches of nationally organized centralized drug procurement were carried out in a row, and the prices of selected drugs were reduced by an average of 53%
.
"Some people think that negotiation is bargaining
.
" Zheng Jie, director of the Beijing Medical Insurance Center, explained that the negotiation is not for bargaining, but to evaluate the true clinical value of drugs through scientific means through fund calculations and find a reasonable price for the common people
.
"Some time ago, there was a 1.
2 million yuan product declaration for medical insurance negotiations, and ultimately did not enter the negotiation process
.
In the future, our goal is still to'guarantee basic'.
The annual treatment and medical insurance payment of the negotiated variety cannot exceed 300,000 yuan, so that the medical insurance fund can maximize Of course, we will also adjust according to market changes
.
" Zheng Jie pointed out that the development of medical insurance this year is no longer a simple matter of a drug entering the catalog.
It is necessary to monitor changes in the entire market through dynamic means to allow more high-quality drugs to pass negotiations.
Enter the medical insurance catalog
.
The "China Medical Insurance Drug Administration Reform Progress and Effect Blue Book" released by the Chinese Pharmaceutical Association shows that since 2018, the proportion of medical insurance drugs used in medical institutions has increased year by year, the dominant position has been further consolidated, and the rationality of clinical drug use has been improved
.
The price level of commonly used drugs has dropped significantly, and the level of drug protection for major diseases and special populations has increased significantly
.
The entry of innovative drugs into medical insurance has accelerated, the cycle has been greatly shortened, and the accessibility of patients has been significantly improved
.